ReviewBiomedicines2021
Cisplatin Mouse Models: Treatment, Toxicity and Translatability.
Review in Biomedicines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Animal Models for Studying Protein-Bound Uremic Toxin Removal-A Systematic Review.International journal of molecular sciences · 2023Pooled it
- The antioxidant and anti-inflammatory activities of avasopasem manganese in age-associated, cisplatin-induced renal injury.Redox biology · 2024Trial
- Salidroside in heavy metal toxicity: a mechanistic review of antioxidant, anti-inflammatory, and anti-apoptotic pathways.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2026Review
- Echinacoside Alleviates Cisplatin-Induced Acute Kidney Injury by Regulating Bap1 to Inhibit Ferroptosis.Biomedicines · 2026Article
- Gastrodin mitigates cisplatin-induced cardiotoxicity in Swiss albino mice by restoring redox homeostasis and modulating the p62-Keap1-Nrf2 Axis.Molecular biology reports · 2026Article
- Genetically distinct microenvironment determines cancer survival and response to therapy in mice.bioRxiv : the preprint server for biology · 2026Article
- Development of a noninvasive murine model of hyperthermic intraperitoneal chemotherapy (HIPEC) treatment for ovarian cancer.Research square · 2026Article
- Glycine as a potential neuroprotective adjuvant to reduce cisplatin-induced brain inflammation in mice.BMC neuroscience · 2026Article
- Article
- Neuroprotective effects of glycine against cisplatin-induced cognitive decline in mice.Annals of medicine and surgery (2012) · 2026Article
- Naringin and hesperidin protect ovarian granulosa cells from cisplatin-induced mitochondrial dysfunction by enhancing bioenergetics and mitophagy.Biology direct · 2026Article
- Construction, evaluation, and applications of renal barrier-on-a-chip system.Bioactive materials · 2026Review
- Improving Laboratory-Based Cancer Drug Discovery Study Designs for Better Research Translations.Methods and protocols · 2026Review
- Article
- Ameliorative effects of gum Arabic-coated selenium nanoparticles on Cisplatin-induced cerebellar neurotoxicity in rats.Scientific reports · 2026Article
- CD44 Targeting of Cisplatin-Loaded Hyaluronic Acid-Modified Mesoporous Silica Nanoparticles for Lung Adenocarcinoma: Synthesis, Characterization, In Vitro and In Vivo Evaluation.Pharmaceutics · 2026Article
- Synergistic therapeutic impact of dichloroacetate nanoparticles and doxorubicin in modulating pyruvate dehydrogenase kinase in breast carcinoma model.Scientific reports · 2026Article
- A Microfibrous Extracellular Matrix Platform forACS pharmacology & translational science · 2026Article
- Caffeine attenuates cisplatin induced microglial reactivity and cognitive dysfunction.Frontiers in molecular neuroscience · 2026Article
- Protective Effects ofJournal of toxicology · 2026Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
Cisplatin is one of the most widely used chemotherapeutic drugs in the treatment of a wide range of pediatric and adult malignances. However, it has various side effects which limit its use. Cisplatin mouse models are widely used in studies investigating cisplatin therapeutic and toxic effects. However, despite numerous promising results, no significant improvement in treatment outcome has been achieved in humans. There are many drawbacks in the currently used cisplatin protocols in mice. In the paper, the most characterized cisplatin protocols are summarized together with weaknesses that need to be improved in future studies, including hydration and supportive care. As demonstrated, mice respond to cisplatin treatment in similar ways to humans. The paper thus aims to illustrate the complexity of cisplatin side effects (nephrotoxicity, gastrointestinal toxicity, neurotoxicity, ototoxicity and myelotoxicity) and the interconnectedness and interdependence of pathomechanisms among tissues and organs in a dose- and time-dependent manner. The paper offers knowledge that can help design future studies more efficiently and interpret study outcomes more critically. If we want to understand molecular mechanisms and find therapeutic agents that would have a potential benefit in clinics, we need to change our approach and start to treat animals as patients and not as tools.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.